Skip to content
DataLookout
Menu

NCT06023030

An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan

StatusCompleted
PhaseNot specified
SponsorAbbVie
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 32 versions: 28 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 6 words Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Nov 2026 to Sep 11, 2026
    • Enrollment target: estimated 240 to confirmed 253
    • Site details revised at 104 of 104 sites
  2. Minor Study sites: 101 to 104
    • Study completion date: Nov 2026 to May 2027
    v31
  3. Minor Study sites: 94 to 101v30
  4. Minor Study sites: 87 to 94v29
  5. Minor Study sites: 83 to 87v28
Show 22 earlier versionsHide 22 earlier versions
  1. Minor Study sites: 82 to 83v27
  2. Minor Study sites: 81 to 82v26
  3. Minor Study sites: 73 to 81v25
  4. Minor Study sites: 71 to 73v24
  5. Minor Study sites: 70 to 71v23
  6. Minor Study sites: 66 to 70
    • Primary and study completion dates: Nov 30, 2026 to Nov 2026
    v22
  7. Minor Study sites: 65 to 66v20
  8. Minor Study sites: 64 to 65v19
  9. Minor Study sites: 61 to 64v18
  10. Minor Study sites: 59 to 61v17
  11. Minor Study sites revised (59)v16
  12. Minor Study sites: 39 to 59v15
  13. Minor Study sites: 36 to 39v13
  14. Minor Study sites: 35 to 36v12
  15. Minor Study sites: 34 to 35v11
  16. Minor Study sites: 27 to 34v10
  17. Minor Study sites: 26 to 27v8
  18. Minor Study sites: 25 to 26v7
  19. Minor Study sites: 14 to 25v5
  20. Minor Study sites: 12 to 14v4
  21. Minor Study sites: 3 to 12v3
  22. Minor Study sites: 2 to 3v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants with Drug Related Serious Infections
Timeframe: Up to 64 Weeks

Arms and interventions

Upadacitinib

Participants will receive upadacitinib as prescribed by their physician according to local label.

Sites

104 sites in 1 country